周二上午，港股创新药板块出现明显调整，其中中国生物制药（01177）盘中大跌5.05%，引发市场关注。作为港股通创新药ETF（520880）的重要成分股之一，中国生物制药的股价走势反映了整个创新药板块的普遍趋势。
据市场数据显示，港股通创新药ETF（520880）今日高开低走，截至发稿时跌幅达1.74%，成交额超1.4亿元。除中国生物制药外，其他创新药股如映恩生物-B（09606）跌超7%，石药集团（01093）跌超3%，呈现出普跌态势。这一走势表明，创新药板块可能正面临短期调整压力。
尽管短期内股价波动加大，但分析人士仍对创新药行业的长期发展保持乐观。华创证券指出，创新药行业正从数量逻辑向质量逻辑转换，进入"产品为王"的阶段。兴业证券则强调，创新药板块的景气度有望持续，中国创新药企业的全球竞争力正不断增强。政策方面，香港特区政府近期提出推动"大湾区临床试验协作平台"建设，国家药监局也优化了创新药临床试验审评审批流程，这些举措有望加速创新药的审批和成果转化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.